Live viruses to treat cancer

Journal of the Royal Society of Medicine

Volumn 106, Issue 8, 2013, Pages 310-314

  Donnelly, Oliver ^a   Harrington, Kevin ^b   Melcher, Alan ^a   Pandha, Hardev ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Oncolytic virotherapy, immunotherapy, delivery, cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; IMMUNOMODULATING AGENT; INTERFERON; LONTUCIREV; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; PACLITAXEL; PEXASTIMOGENE DEVACIREPVEC; PROTEIN TYROSINE KINASE INHIBITOR; REOLYSIN; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; LIVER CELL CARCINOMA; METASTATIC MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REOVIRUS; TUMOR IMMUNITY; VIRAL CLEARANCE; VIRAL TROPISM; VIRUS ENTRY; VIRUS REPLICATION;

EID: 84883187254     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/0141076813494196     Document Type: Article

References (16)

1. Kelly E and Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-5.
2. Vä hä -Koskela MJ, Heikkilä J.E and Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
3. Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20: 1119-32.
4. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008; 15: 911-20.
5. Wojton J and Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010; 21: 127-34.
6. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-37.
7. Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012; 4: 138ra77.
8. Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080-9.
9. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-71.
10. Liu TC, Hwang T, Park BH, Bell J and Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-42.
11. See http://www.amgen.com/media/media_pr_detail.jsp?releaseID1/41519312.
12. Langfield KK, Wegman TR, Walker HJ, et al. Production and purification of measles virus for oncolytic virotherapy clinical trials. Mol Ther 2004; 9: S31.
13. Roulstone V, Twigger K, Zaidi S, et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 2013; 20: 521-8.
14. Touchefeu Y, Vassaux G and Harrington KJ. Oncolytic viruses in radiation oncology. Radiother Oncol 2011; 99: 262-70.
15. Richard-Fiardo P, Franken PR, Harrington KJ, Vassaux G and Cambien B. The use of molecular imaging of gene expression by radiotracers in gene therapy. Expert Opin Biol Ther 2011; 11: 1273-85.
16. Pandha HS, Heinemann L, Simpson GR, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158-66.